Assistant Professor, Pathology, Oregon Health and Science University School of Medicine
Pathology
Dr. Marc M. Loriaux, MD
|
|
Give Review
Marc Loriaux practices Pathology. He went to medical school at Oregon Health & Science University School of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification". Marc Loriaux has written publications. He has 56 publications published with PubMed. The lastest paper is: 'Polyurethane-coated Dacron-covered stent-grafts for TIPS: results in swine.' He accepts all Medicare patients.
Publications
- The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
- BCR-ABL1 promotes Leukemia by converting p27 into a cytoplasmic oncoprotein.
- A potential therapeutic strategy for chronic lymphocytic Leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
- The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
- CX-4945, a selective inhibitor of casein kinase 2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in Chronic lymphocytic le...
- Oncogenic CSF3R mutations in chronic neutrophilic Leukemia and atypical CML.
- Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-? and Src in Tumor Growth.
- A Case Study of Personalized Therapy for Osteosarcoma.
- HitWalker: variant prioritization for personalized functional cancer genomics.
- The selective Syk inhibitor P505-15 inhibits B cell signaling and function in vitro and in vivo, and augments the activity of fludarabine in chronic lymphocytic Leukemia.
- Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia.
- Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening.
- Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
- Creation of Fibrinogen-enhanced Experimental Blood Clots to Evaluate Mechanical Thrombectomy Devices for Treatment of Acute Stroke: An In Vitro Study.
- Multiplex high-throughput gene mutation analysis in Acute myeloid leukemia.
- Newly described activating JAK3 mutations in T-cell Acute lymphoblastic leukemia.
- TNF? facilitates clonal expansion of JAK2V617F positive Cells in myeloproliferative neoplasms.
- Potent activity of ponatinib (AP24534) in models of FLT3-driven Acute myeloid leukemia (AML) and other hematologic malignancies.
- CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-Cell malignancies, inhibits PI3K signaling and Cellular viability.
- MET receptor sequence variants R970C and T992I lack transforming capacity.
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine Myeloproliferative neoplasms.
- A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid Leukemia patients treated with imatinib.
- AP24534, a pan-BCR-ABL inhibitor for chronic myeloid Leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
- RNAi screen for rapid therapeutic target identification in Leukemia patients.
- High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid Leukemia patients.
- High-throughput sequence analysis of the tyrosine kinome in Acute myeloid leukemia.
- Fallopian tube occlusion with use of a small intestine submucosa device: evaluation in a rabbit model.
- Lack of suitability of the rabbit model for particulate uterine artery embolization.
- Bifurcated drum occluder endograft for treatment of abdominal aortic aneurysm: an experimental study in dogs.
- The square stent-based large vessel occluder: an experimental pilot study.
- Ph-positive and -negative myeloproliferative Syndromes may co-exist.
- Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous Leukemia during major cytogenetic responses induced by imatinib ...
- [The consequences of the demographic revolution and of the aging of society: restructuring the age groups and modifying intergenerational relations].
- Polyurethane-coated Dacron-covered stent-grafts for TIPS: results in swine.
- Engineered leucine zippers show that hemiphosphorylated CREB complexes are transcriptionally active.
- Modulatory function of CREB.CREM alpha heterodimers depends upon CREM alpha phosphorylation.
- Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
- RNAi screening of the tyrosine kinome identifies therapeutic targets in Acute myeloid leukemia.
- Characterization of murine JAK2V617F-positive Myeloproliferative disease.
- Activating alleles of JAK3 in Acute megakaryoblastic leukemia.
- Establishment of a murine model of aggressive systemic mastocytosis/mast cell Leukemia.
- Acute graft-versus-host disease of the heart.
- The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and Acute myeloid leukemia, but not in Acute lymphoblastic leukemia or chronic lymphocytic ...
- Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid Leukemia patients treated with imatinib.
- c-CBL is not required for Leukemia induction by Bcr-Abl in mice.
- Stent-grafts for de novo TIPS: technique and early results.
- High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic Leukemia.
- Absence of SKP2 expression attenuates BCR-ABL-induced Myeloproliferative disease.
- Functional characterization of an activating TEK mutation in Acute myeloid leukemia: a cellular context-dependent activating mutation.
- A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce Leukemia in mice.
- Thrombus formation after percutaneous catheterization and manual compression of the femoral artery in heparinized sheep.
- Small intestinal submucosa plug for closure of dilated nephrostomy tracts: a pilot study in swine.
- Human chronic myeloid Leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
- Survey of activated FLT3 signaling in Leukemia.
- Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and Myelodysplastic/myeloproliferative neoplasms.
Schools
Or Hlth Sci Univ Sch Of Med
Or Health Science University Hospital
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
- Hematopathology
- Pathology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Oregon Health & Science University -
Oregon Health & Science University School of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1215943824 |
| Last Name Of The Provider | LORIAUX |
| First Name Of The Provider | MARC |
| View All |
Similar Doctors
|
Dr. Gerald M. Segal, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jody L. Kujovich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas G. Deloughery, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Tarunpreet Bains, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kim-Hien T. Dao, DO |
|
|
Dr. Xiaohong Cai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen R. Macdonell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Sauer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric C. Anderson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amariek J. Jensen-De La Cruz, MD |
|
|
Dr. Julia H. Fei, MD |
|
|
Dr. Maria G. Gregorio, MD |